ArticleNeurourology and urodynamics2020
Long-term real-life adherence of percutaneous tibial nerve stimulation in over 400 patients.
Article in Neurourology and urodynamics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Comparison of different types of therapy for overactive bladder: A systematic review and network meta-analysis.Frontiers in medicine · 2022Pooled it
- Implantable tibial neuromodulation with an Anklet for overactive bladder: a review.World journal of urology · 2026Review
- Article
- Efficacy and sex-specific outcomes after six episodes of percutaneous tibial nerve stimulation treatment on overactive bladder syndrome symptoms.Frontiers in urology · 2024Article
- Adherence to Overactive Bladder Syndrome Treatments Recent Developments and Future Perspectives.International journal of women's health · 2023Review
- Barriers and facilitators to overactive bladder therapy adherence.Neurourology and urodynamics · 2022Review
- Third-line therapy for overactive bladder in the elderly: Nuances and considerations.Neurourology and urodynamics · 2022Review
- Patient-tailored healthcare and tibial nerve neuromodulation in the treatment of patients with overactive bladder symptoms.Neurourology and urodynamics · 2022Article
- Percutaneous tibial nerve stimulation maintenance therapy for overactive bladder in women: long-term success rates and adherence.International urogynecology journal · 2021Article
- Long-term real-life adherence of percutaneous tibial nerve stimulation in over 400 patients.Neurourology and urodynamics · 2020Article
- Real-life patient experiences of TTNS in the treatment of overactive bladder syndrome.Therapeutic advances in urologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPercutaneous tibial nerve stimulation (PTNS) is used as a treatment to reduce the complaints of overactive bladder (OAB). Although it is rewarding therapy patients need maintenance treatment to preserve the beneficial effect.
aimThis real-life retrospective study was performed to assess the feasibility of PTNS adherence. MATERIALS &
methodsAll patients who underwent PTNS were retrospectively included. We analyzed the following: indication, kind of treatments (pharmacologic and third-line therapy) before and after PTNS treatment, time and reason for quitting therapy. Statistical analysis was done by performing competitive-risk analysis and Kaplan-Meier curves. Patients were categorized into four groups. Group 1: all patients; group 2: all patients on maintenance PTNS therapy (continuing after 12 weeks); group 3: patients on maintenance PTNS therapy excluding the following: (a) patients with initial good response who seized treatment due to death, (b) patient who successfully switched to transcutaneous stimulation, (c) patients who were cured of their OAB symptoms, or (d) patients who relocated; and group 4: group 3 but excluding those who stopped treatment because of nonmedical reasons (physical strain, inconveniencies associated with visiting the hospital).
resultsFour-hundred two patients (70% female) with a median age of 70 years underwent PTNS. Underlying treatment indications were: OAB-wet (54%) and OAB-dry (29%). The median follow-up (FU) of group 1 was 4 months. Fifty-seven percent (N = 228) of the patients received maintenance PTNS therapy. Median FU in group 4 was 46 months (range, 3-111 months). Over 40% of the maintenance patients stopped PTNS because of logistic reasons and physical strain during an FU time of 6 years.
conclusionThe real-world data described here with is in line with earlier published work in terms of the success rate of OAB treatment. However, over 40% quit their therapy due to nonmedical reasons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.